T-helper-1 and T-helper-2 responses in psychiatric disorders

Brain, Behavior, and Immunity

Volumn 15, Issue 4, 2001, Pages 340-370

  Schwarz, Markus J ^a   Chiang, Sonnig ^a   Müller, Norbert ^a   Ackenheil, Manfred ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adaptive immune system; Alzheimer's disease; Immunopsychiatry; Major depression; Psychoneuroimmunology; Schizophrenia; Th1; Th2

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADAPTATION; AFFECTIVE NEUROSIS; ALZHEIMER DISEASE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DEPRESSION; HELPER CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TH1 CELL; TH2 CELL;

EID: 0035671306     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1006/brbi.2001.0647     Document Type: Article

References (247)

1. Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis
2. Inflammation and Alzheimer's disease
3. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration
4. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells
5. Regulation of T-cell responses by CNS antigen-presenting cells: Different roles for microglia and astrocytes
6. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation
7. Serum antibodies to herpes simplex virus types I and II in depressed patients
8. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma
9. Cytokines: Coordinators of immune and inflammatory responses
10. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment
11. Production of interferon-gamma in families with multiple occurrence of schizophrenia
12. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors
13. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
14. Serum cytokine concentrations in patients with schizophrenia
15. Role of cytokines in human B lymphocyte growth and differentiation
16. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients
17. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
18. IL-6: Insights into novel biological activities
19. CD40 engagement stimulates IL-12 p70 production by human microglial cells: Basis for Th1 polarization in the CNS
20. Acute phase proteins in major depression
21. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
22. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
23. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10
24. T-lymphocyte interleukin 6 receptor binding in patients with dementia of Alzheimer type
25. T-cell tumour necrosis factor-alpha receptor binding in demented patients
26. Heterogeneity of helper/inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes
27. Blood levels of cytokines in elderly patients with major depressive disorder
28. A high plasma concentration of TNF-alpha is associated with dementia in centenarians
29. Norepinephrine in depressive reactions: A review
30. Activated mast cells produce interleukin 13
31. Effect of interferon on severe psychiatric diseases
32. The functional characterization of interleukin-10 receptor expression on human natural killer cells
33. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide
34. Cytokine profiles in drug-naive schizophrenic patients
35. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour
36. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM + IgD + B cell line
37. Neuroprotective role of IL-4 against activated microglia
38. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease
39. IL-10: A novel cytotoxic T cell differentiation factor
40. Cytokine function: A study in biologic diversity
41. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins
42. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
43. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes
44. Cytokine-induced sickness behavior: Where do we stand?
45. Human Th1 and Th2 lymphocytes: Their role in the pathophysiology of atopy
46. Interleukin-18
47. Interleukin-1 alpha and interleukin-2 in cerebro-spinal fluid of schizophrenic subjects
48. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type
49. Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction
50. The instructive role of innate immunity in the acquired immune response
51. Cytokines in acute and chronic inflammation
52. Labordiagnostik neurologischer erkrankungen
53. Soluble cytokine receptors: Their roles in immunoregulation, disease, and therapy
54. Elevated circulating tumor necrosis factor levels in Alzheimer's disease
55. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
56. Microglia induce CD4 T lymphocyte final effector function and death
57. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission
58. Interleukin-6 (IL-6) - A molecule with both beneficial and destructive potentials
59. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta 1
60. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms
61. Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production
62. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects
63. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness
64. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection
65. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients
66. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected
67. Structure and expression of murine germ-line immunoglobulin epsilon heavy chain transcripts induced by interleukin 4
68. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15
69. Interleukin 18 - Interferon gamma inducing factor - A novel player in tumour immunotherapy?
70. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF
71. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis
72. Relationship of serum TSH concentration and antithyroid antibodies to diagnosis and DST response in psychiatric inpatients
73. Astrocytic factors deactivate antigen presenting cells that invade the central nervous system
74. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease
75. Discriminant power of combined cerebrospinal fluid tau protein and soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
76. Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10
77. Murine fetal resorption and experimental pre-eclampsia are induced by both excessive Th1 and Th2 activation
78. Antiseptal brain antibody in IgG of schizophrenic patients
79. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients
80. IL-6 cytokine family and signal transduction: A model of the cytokine system
81. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
82. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages
83. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage
84. IL-2 and IL-6 secretion in dementia: Correlation with type and severity of disease
85. Transforming growth factor-beta does not alter interleukin-1 expression in cultured human macrophages
86. Interferon responses in schizophrenia and major depressive disorders
87. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
88. Serum interleukin-6 levels correlate with the severity of dementia in down syndrome and in Alzheimer's disease
89. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders
90. Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia
91. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes
92. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia
93. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics
94. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics
95. Decreased interleukin-2 production in Korean schizophrenic patients
96. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha
97. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis
98. In vivo immunomodulation following intradermal injection with DNA encoding IL-18
99. Microglia: A sensor for pathological events in the CNS
100. CD28 constimulation accelerates IL-4 receptor sensitivity and IL-4-mediated Th2 differentiation
101. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody
102. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements
103. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzhelmer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha 1-antichymotrypsin
104. Ober die Liquordiagnose der Schizophrenien [About CSF diagnosis of schizophrenia]
105. The effects of psychological stress on plasma interleukin-6 activity in rats
106. Low CSF soluble interleukin 2 receptor levels in acute depression. Short communication
107. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain?
108. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
109. Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders
110. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6
111. Expression cloning and characterization of a human 1L-10 receptor
112. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals
113. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells
114. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics
115. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers
116. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression
117. In vivo immunomodulatory effects of clozapine in schizophrenia
118. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs
119. Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients
120. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression
121. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression
122. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression
123. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response
124. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion
125. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses
126. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients
127. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations
128. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
129. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis
130. Increased numbers of CD5+ B lymphocytes in schizophrenic patients
131. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status
132. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
133. A distinct role for interleukin-13 in Th2-cell-mediated immune responses
134. Activation of microglial cells by beta-amyloid protein and interferon-gamma
135. Involvement of the tumor necrosis factor receptor p75 in mediating cytotoxicity and gene regulating activities
136. Innate immune recognition and control of adaptive immune responses
137. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation?
138. Immune activation in non-treated suicidal major depression
139. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production
140. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma
141. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease
142. Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain
143. Are all antidepressants the same?
144. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment
145. Regulation of IgG1 and IgE synthesis by interleukin 4 in mouse B cells
146. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
147. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: Relationship to negative symptomatology
148. Cellular immunity in schizophrenic patients before and during neuroleptic treatment
149. Inhibition of T cell proliferation by macrophage tryptophan catabolism
150. Interleukin 5 and interleukin 3 induce serine and tyrosine phosphorylations of several cellular proteins in an interleukin 5-dependent cell line
151. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?
152. Elevated circulating levels of IL-6 in schizophrenia
153. CSF 5-HIAA predicts suicide risk after attempted suicide
154. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder
155. Anti-inflammatory cytokines
156. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18)
157. Influence of therapy on antibody-formation
158. Interleukin-4 and interferon-gamma: The quintessence of a mutual antagonistic relationship
159. Molecular cloning of a partial cDNA of the interleukin-2 receptor-beta in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells
160. Molecular cloning of the coding sequence of an interleukin-2 receptor alpha subunit cDNA in murine brain
161. Molecular cloning of the cDNA coding sequence of IL-2 receptor-gamma (gammac) from human and murine forebrain: Expression in the hippocampus in situ and by brain cells in vitro
162. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2
163. Immunoregulators in the nervous system
164. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
165. Smoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia
166. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
167. Elevation of CD5+ B lymphocytes in schizophrenia
168. IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells
169. Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule
170. Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment
171. Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes
172. Chemokines in neurological disease models: Correlation between chemokine expression patterns and inflammatory pathology
173. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
174. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients
175. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers
176. Patients with Alzheimer's disease display a pro-inflammatory phenotype
177. Interferon sensitivity of fibroblast cell cultures derived from patients with neoplasms of the head and neck
178. Interleukin-6 mRNA expression by cortical neurons in culture: Evidence for neuronal sources of interleukin-6 production in the brain
179. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta
180. Biology of human TH1 and TH2 cells
181. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness
182. Immunological dysfunction in schizophrenia: A systematic approach
183. CSF corticotropin-releasing hormone in depressed patients and normal control subjects
184. Hepatitis B vaccination in psychiatric patients
185. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells
186. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10
187. No evidence for autoimmunity in schizophrenia
188. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
189. Defective production of interleukin-6 by monocytes: A possible mechanism underlying several host defense deficiencies of neonates
190. The catecholamine hypothesis of affective disorders: A review of supporting evidence
191. Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta
192. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine
193. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms
194. Antibodies to heat shock proteins in schizophrenic patients: Implications for the mechanism of the disease
195. Autoantibodies against 60-kD heat shock protein in schizophrenia
196. Acquisition of lymphokine-producing phenotype by CD4+ T cells
197. Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils
198. Increased CD56+ natural killer cells and related cytokines in major depression
199. Circulating cytokines in Alzheimer's disease
200. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients
201. Indicators of immune activation in major depression
202. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence
203. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit
204. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease
205. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression
206. Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist
207. Central beta-amyloid peptide-induced peripheral interleukin-6 response in mice
208. Functional characterization of human IL-10
209. Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia
210. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever
211. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: No alteration of soluble gp130
212. The common gamma-chain for multiple cytokine receptors
213. Antibody reactivity to brain membrane proteins in serum from schizophrenic patients
214. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: The roles of cytokines and CD40
215. IL-4, IL-10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line
216. Gp130 and the interleukin-6 family of cytokines
217. Murine models of cancer cytokine gene therapy using interleukin-12
218. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils
219. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation
220. The IL-2/IL-2 receptor system: A current overview
221. Transforming growth factor-beta protein and messenger RNA expression is increased in the closing ductus arteriosus
222. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia
223. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10
224. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients
225. Retinoids as Ig isotype-switch modulators. The role of retinoids in directing isotype switching to IgA and IgG1 (IgE) in association with IL-4 and IL-5
226. Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production
227. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells
228. A critical role for IL-18 in the proliferation and activation of NK1.1+CD3-cells
229. Immunoregulatory roles of interleukin-13 in cattle
230. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
231. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation
232. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients
233. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
234. Negative association between schizophrenia and rheumatoid arthritis
235. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution
236. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism
237. The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta
238. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia
239. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells
240. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
241. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia
242. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia
243. Structure-function analysis of human IL-6 receptor: Dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130
244. IL-10 is produced by subsets of human CD + T cell clones and peripheral blood T cells
245. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
246. Exposure to physical and psychological stressors elevates plasma interleukin 6: Relationship to the activation of hypothalamic-pituitary-adrenal axis
247. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4